Gennaro Pagano, Kirsten I Taylor, Judith Anzures Cabrera, Tanya Simuni, Kenneth Marek, Ronald B Postuma, Nicola Pavese, Fabrizio Stocchi, Kathrin Brockmann, Hanno Svoboda, Dylan Trundell, Annabelle Monnet, Rachelle Doody, Paulo Fontoura, Geoffrey A Kerchner, Patrik Brundin, Tania Nikolcheva, Azad Bonni
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson's disease. Although in the PASADENA phase 2 study, the primary endpoint (Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) sum of Parts I + II + III) was not met, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants (MDS-UPDRS Part III)...
April 15, 2024: Nature Medicine